Ivermectin + Mebendazole: Groundbreaking Study Reports 84.4% Clinical Benefit Rate in Cancer Patients

An observational analysis reported that 84.4% of cancer patients treated off-label with a compounded combination of ivermectin and mebendazole experienced what researchers defined as clinical benefit. The analysis did not specify the number of patients included, the types of cancer studied, the duration of follow-up, or the specific criteria used to measure clinical benefit. No peer-reviewed publication of the findings was identified. Off-label use of medications occurs outside FDA-approved indications and without the regulatory oversight required for standard cancer treatments.

Next story